Sarepta's new CEO faces critical tests to prove growth
Sarepta's new CEO faces critical tests to prove growth
Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular and central nervous system diseases.
Company Info
Sector:Biopharmaceutical
Headquarters:Cambridge, Massachusetts, United States
Founded:1980
Website:www.sarepta.com/
Upcoming Milestones & Key Dates
2027-Q1
Clinical
Elevidys label expansion data
Clinical Development Pipeline
Elevidys
Target: Micro-dystrophinSRP-9001
Target: Gene therapySRP-5051
Target: Exon 51 skippingRecent News
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
Sarepta names former AbbVie R&D exec Michael Severino as next CEO.
Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil
Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil.
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail — BioSpace coverage of biopharma industry developments.
Leadership Team
Doug Ingram
President and Chief Executive Officer
Louise Rodino-Klapac
Chief Scientific Officer
Ian Estepan
Chief Financial Officer